BioGaia invests in a drug against NEC
February 21, 2014

The board of BioGaia has decided to invest in the first phase of a long-term project aimed at developing a drug with rigorous hygiene, analysis and documentation requirements, to treat the highly fatal disease Necrotising Enterocolitis (NEC), which affects premature infants. BioGaia will invest SEK 42 million in the project over a two-year period. The project will be driven by BioGaia’s subsidiary Infant Bacterial Therapeutics (IBT), of which 9% is owned by the company’s President, Staffan Strömberg, and its Research Director, Eamonn Connolly. The remaining 91% is owned by BioGaia.
Read the official press release here